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Overexpression	  of	  MYC	   is	  widespread	   in	   human	   cancer,	   often	   as	   a	   consequence	  of	  mutation	   in	  
upstream	  mitogenic	  pathways	   such	  as	  EGFR-­‐RAS	  and	  WNT-­‐βCatenin.	  Deregulated	  MYC	  perturbs	  
many	   aspects	   of	   cell	   function	   but	   its	   influence	   on	   cellular	   metabolism	   may	   impart	   specific	  
vulnerabilities	  that	  can	  be	  exploited	  for	  cancer	  therapy	  (1).	  Two	  new	  studies	  shine	  the	  spotlight	  on	  
oxidative	   stress	   as	   a	   specific	   vulnerability	   in	  MYC-­‐dependent	   cancers	   and	   pinpoint	   NUAK1	   and	  
AMPK	  as	  key	  participants	  in	  how	  cancer	  cells	  cope	  with	  oxidative	  stress	  (2,	  3).	  
	   Our	   previous	   work	   identified	   NUAK1	   (aka	   ARK5)	   and	   AMPKα1	   as	   synthetic	   lethal	  
interactors	  with	  overexpressed	  MYC	  (4).	  Colorectal	  cancer	  (CRC)	  is	  characterised	  by	  near	  uniform	  
overexpression	  of	  MYC	  (5)	  suggesting	  that	  CRC	  may	  be	  particularly	  dependent	  upon	  these	  kinases.	  
Supporting	  this	  hypothesis,	  we	  have	  now	  found	  that	  genetic	  deletion	  of	  Nuak1	  suppresses	  tumour	  
formation	   in	   a	  mouse	  model	   of	   CRC,	   while	   acute	   depletion	   of	   Nuak1	   drives	   regression	   of	   pre-­‐
existing	   colonic	   tumours	   (2).	   Transcriptomic	   analysis	   revealed	   that	   loss	   of	   NUAK1	   suppressed	  
expression	   of	   a	   host	   of	   anti-­‐oxidant	   genes,	   focusing	   our	   attention	   on	   the	   anti-­‐oxidant	  
transcriptional	   master	   regulator	   NRF2	   (NFE2L2).	   In	   unstressed	   cells	   NRF2	   is	   targeted	   for	  
degradation	   a)	   by	   the	   cytosolic	   ubiquitin	   ligase	   KEAP1	   and	   b)	   via	   GSK3β-­‐dependent	  
phosphorylation	   (6,	   7).	   Reactive	   Oxygen	   species	   (ROS)	   drive	   nuclear	   stabilization	   of	   NRF2	   by	  
directly	  modulating	  KEAP1	  and	  by	  indirectly	  suppressing	  GSK3β,	  the	  latter	  via	  inhibition	  of	  PTEN,	  
allowing	  inhibitory	  phosphorylation	  of	  GSK3β	  by	  AKT.	  We	  found	  that	  this	  latter	  pathway	  requires	  
concomitant	   suppression	   of	   the	   protein	   phosphatase	   PP1β,	   which	   otherwise	   counteracts	   AKT-­‐
dependent	  GSK3β	   phosphorylation	   (8).	  NUAK1	  was	  previously	   shown	   to	   inhibit	   PP1β	   activity	  by	  
phosphorylating	   the	   substrate-­‐targeting	   subunit,	   MYPT1	   (9).	   Strikingly,	   we	   found	   that	   ROS	  
activates	   NUAK1	   kinase	   activity,	   possibly	   via	   direct	   oxidation	   of	   multiple	   NUAK1	   Cysteines,	  
resulting	   in	   increased	   inhibitory	   phosphorylation	   of	   the	   MYPT1/PP1β	   complex.	   Depletion	   or	  
inhibition	  of	  NUAK1	  thus	  allows	  unrestrained	  PP1β-­‐dependent	  de-­‐phosphorylation	  of	  the	  AKT	  site	  
on	  GSK3β, with	  the	  consequence	  that	  nuclear	  NRF2	  fails	  to	  accumulate	  and	  ROS	  levels	  breach	  the	  
threshold	   for	   loss	   of	   viability.	   Crucially,	   provision	   of	   exogenous	   anti-­‐oxidants	   protected	  
autochthonous	   CRC	   tumours	   from	  NUAK1	   depletion,	   confirming	   the	   functional	   requirement	   for	  
NUAK1	  to	  suppress	  oxidative	  stress	  (2).	  	  	  
Relating	   the	   genetic	   model	   to	   human	   disease,	   multiple	   human	   CRC	   cell	   lines	   were	  
exquisitely	  sensitive	  to	  pharmacological	  inhibition	  of	  NUAK1	  and	  again	  were	  rescued	  by	  provision	  
of	  exogenous	  anti-­‐oxidants.	  Tellingly,	  the	  human	  CRC	  cell	  lines	  were	  also	  rescued	  by	  depletion	  of	  
cMYC,	  whereas	  forced	  expression	  of	  MYC	  in	  drug-­‐resistant	  cells	  conferred	  sensitivity	  to	  the	  NUAK1	  
inhibitor,	   firmly	   supporting	   our	   previous	   demonstration	   of	   a	   synthetic	   lethal	   requirement	   for	  
NUAK1	  in	  MYC-­‐deregulated	  cells	  (4).	  
A	  separate	  study	  by	  Radtke	  and	  colleagues	  has	  now	  revealed	  a	  similar	   role	   for	  AMPK,	  or	  
rather,	  for	  a	  specific	  subset	  of	  AMPK	  complexes,	  in	  MYC-­‐dependent	  Melanoma	  (3).	  Although	  often	  
discussed	  as	  though	  it	  were	  a	  single	  entity,	  the	  AMP-­‐activated	  protein	  kinase	  is	  a	  trimeric	  complex	  
comprised	  of	  1	  of	  2α,	  1	  of	  2β	   and	  1	  of	  3γ	   subunits,	  and	   there	   is	  evidence	   that	  multiple	  distinct	  
complexes	   can	   assemble	   and	   co-­‐exist	   in	   cells,	   presumably	   responding	   to	   distinct	   cues	   and/or	  
regulating	  specific	  downstream	  substrates	  (10).	   	  The	  α1	  and	  β2	  subunits	  of	  AMPK	  are	  selectively	  
amplified	   across	   a	   spectrum	  of	   human	   cancers,	   suggesting	   a	   specific	   enrichment	   for	   complexes	  
containing	  these	  subunits	  in	  a	  cancer	  setting	  (11).	  	  Using	  a	  mouse	  model	  of	  Melanoma	  driven	  by	  
NRAS	   activation	   in	   the	   absence	   of	   Ink4a	   (Cdkn2a),	   the	   Radtke	   group	   found	   that	   elevated	  
expression	  of	  both	  of	   these	  AMPK	   subunits	   correlated	  with	  high	  MYC	  expression	  at	   the	   cellular	  
level	   in	   FACS-­‐sorted	   disaggregated	   tumour	   cells.	   Suppression	   of	   MYC	   specifically	   reduced	  
expression	  of	  both	  of	  these	  subunits,	  whereas	  the	  β1	  and	  γ1	  subunits	  were	  unaffected,	  providing	  
the	   first	   evidence	   that	   MYC	   may	   selectively	   enrich	   for	   a	   specific	   subset	   of	   AMPK	   complexes.	  
Significantly,	  depletion	  of	  either	  AMPKα1	  or	  β2	  resulted	  in	  pronounced	  apoptosis	  of	  MYC	  positive	  
melanoma	  cells	  (3).	  
In	  contrast	  with	  our	  analysis	  of	  CRC	  cells,	  wherein	  elevated	  MYC	  correlated	  with	  increased	  
cytosolic	  ROS,	  the	  Radtke	  group	  reported	  increased	  ROS	  upon	  depletion	  of	  MYC	  in	  their	  Melanoma	  
model	  and	  indeed,	  genetic	  deletion	  of	  MYC	  alone	  resulted	  in	  pronounced	  cell	  death.	  The	  reason	  
for	   this	   difference	   is	   unclear	   and	  may	   relate	   to	   the	   presence	   of	   distinct	   oncogenic	   drivers	   (RAS	  
activation	  in	  Melanoma	  versus	  APC	  loss	  in	  CRC)	  in	  different	  tissues.	  However,	  treatment	  of	  MYC-­‐
deleted	   cells	   with	   991,	   a	   highly	   selective	   pharmacological	   activator	   of	   AMPK	   (12),	   completely	  
rescued	   both	   the	   elevated	   ROS	   and	   the	   cytotoxic	   effect	   of	   MYC	   deletion,	   mirroring	   the	  
cytoprotective	  role	  of	  NUAK1	  in	  counteracting	  ROS.	  Furthermore,	  as	  is	  the	  case	  for	  high	  expression	  
of	   NUAK1	   in	   CRC,	   high	   expression	   of	   AMPK	   in	  Melanoma	   correlates	   with	   significantly	   reduced	  
overall	  survival	  of	  human	  patients	  (2,	  3).	  
Mitochondrial	   ROS	   production	   is	   intimately	   linked	   to	   Calcium	   signalling	   and	  we	   recently	  
demonstrated	  a	  specific	  role	  for	  NUAK1	  in	  Calcium/CamKKβ-­‐dependent	  activation	  of	  AMPK	  (13),	  
suggesting	  that	  the	  activity	  of	   these	  kinases	   in	  response	  to	  oxidative	  stress	   is	   likely	  coordinated.	  
Cellular	   sensitivity	   to	   Calcium	   flux	   appears	   to	   increase	   with	   MYC	   levels,	   providing	   another	  
potential	   link	   to	   regulation	   of	   these	   kinases.	   From	   MYC’s	   multiple	   roles	   in	   mitochondrial	  
perturbation	  to	  the	  promotion	  of	  nutrient	  uptake,	  much	  of	  which	  are	  diverted	  for	  generation	  of	  
anti-­‐oxidants	  (eg.	  glutathione	  and	  NADPH),	  MYC	  likely	  contributes	  both	  positively	  and	  negatively	  
to	   oxidative	   stress	   (14).	   The	   precise	   level	   of	   MYC	   expression	   coupled	   with	   the	   context	   of	   co-­‐
incident	  mutations	  and	  varying	  exposure	   to	  oxidative	   stress	  will	   all	   contribute	   to	  determine	   the	  
influence	  of	  MYC	  from	  one	  instance	  to	  another.	  Targeting	  the	  defence	  mechanisms	  employed	  by	  
cancer	   cells	   to	   counteract	   oxidative	   stress	   and	   maintain	   ROS	   homeostasis	   may	   well	   improve	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Figure	  Legend	  
The	  role	  of	  NUAK1	  in	  anti-­‐oxidant	  signalling.	  
Reactive	  Oxygen	  species	  mobilise	  the	  anti-­‐oxidant	  master	  regulatory	  transcription	  factor	  NRF2	  by	  
inhibiting	  KEAP1	  and	   indirectly	   suppressing	  GSK3β.  Inhibitory	  phosphorylation	  of	  GSK3β	   by	  AKT	  
requires	   concomitant	   suppression	   of	   the	   PP1β	   phosphatase	   by	   NUAK1.	   	   NRF2	  moreover	   drives	  
expression	  of	  NUAK1,	   firmly	  placing	  NUAK1	   in	   the	  oxidative	   stress	   response	  pathway.	   	  MYC	  has	  
many	  influences	  on	  ROS	  homeostasis	  and	  establishes	  an	  ectopic	  dependency	  on	  the	  NUAK1/NRF2	  
pathway	  to	  sustain	  tumour	  cell	  viability.	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